| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Simon Michel CEO | SIX Exchange | CH0019396990 ISIN |
| CH Country | 2,600 Employees | 3 Jul 2026 Last Dividend | 16 Jun 2022 Last Split | - IPO Date |
Ypsomed Holding AG is a distinguished enterprise that focuses on the innovation, production, and distribution of injection and infusion solutions tailored for the pharmaceutical and biotechnology sectors. The organization is bifurcated into two primary divisions, namely Ypsomed Delivery Systems and Ypsomed Diabetes Care, catering to distinct facets of medical care and delivery mechanisms. With its foundations dating back to 1984, Ypsomed stands as a pioneering entity headquartered in Burgdorf, Switzerland. It maintains a robust operational footprint spreading across Switzerland, Europe, North America, and several other international territories. Ypsomed distinguishes itself in the market through strategic partnerships with pharmaceutical entities, complemented by its own expansive distribution network and collaboration with independent distributors.
This segment of Ypsomed specializes in offering a wide array of injection systems which includes pen injectors, autoinjectors, and wearable injectors alongside intelligent device solutions. Under the YDS brand, Ypsomed provides pioneering solutions designed for ease of use, enhancing patient compliance, and ensuring accurate dosing. Their products cater to various medical needs, supporting the delivery of medications for chronic conditions with precision and reliability.
Focused on the everyday needs of individuals managing diabetes, this division delivers a comprehensive suite of products. The mylife brand oversees the provision of insulin pumps and infusion sets designed for seamless insulin management. Additionally, it offers pen needles and blood glucose monitoring systems to ensure continuous and precise monitoring of blood glucose levels. Accessories and other daily diabetes management tools also form part of this segment's offerings, ensuring individuals living with diabetes have access to comprehensive care solutions.
Ypsomed offers high-precision components that are integral to the medical and pharmaceutical devices they specialize in. This service underscores Ypsomed's commitment to quality and precision in every product and service offered, reflecting their expertise in creating components that meet the strictest standards required in medical device manufacturing.
In addition to its proprietary product lines, Ypsomed leverages its manufacturing expertise to offer contract manufacturing services. This includes the production of bespoke devices and components for pharmaceutical and biotechnology companies. By providing such services, Ypsomed supports the broader healthcare sector with its advanced manufacturing capabilities, facilitating the development and delivery of innovative medical solutions.